# Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

> **NCT06189170** · EARLY_PHASE1 · RECRUITING · sponsor: **Kariya Pharmaceuticals** · enrollment: 88 (estimated)

## Conditions studied

- Safety Issues
- Tolerance

## Interventions

- **DRUG:** KP405
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06189170
- **Lead sponsor:** Kariya Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06189170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06189170, "Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06189170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*